Axcella Health Inc

Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axcella is a clinical-stage biotechnology company that treats complex diseases using endogenous metabolic modulator (EMM) compositions. They combine biological pathways with developments in systems biology and machine learning. Their proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative, and liver conditions.

Mind Medicine MindMed

Novavax

Pharma stocks and the biotech sector can offer explosive gains. It also offers incredibly crushing defeats in which share prices decline precipitously.

3 Pharma Stocks to Dump Before the Damage Is Done

Moderna

Singular Genomics Systems

The biotech sector never fails to offer up stocks full of massive issues at any given time. Developing novel therapeutic devices and pharmaceuticals is, after all, very expensive.

Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now

Here is how Axcella Health Inc. (AXLA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Axcella Health (AXLA) This Year?

Axcella Health (NASDAQ: AXLA ) stock is taking a beating on Friday after the biotechnology company announced plans for a reverse stock split. According to Axcella Health, shares of AXLA stock are going to undergo a one-for-25 reverse split.

Why Is Axcella Health (AXLA) Stock Down 24% Today?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company's common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on September 18, 2023, after close of trading on The Na.

Axcella Announces Reverse Stock Split Effective September 19, 2023

Trading a short squeeze is a strategy where you find heavily shorted stocks and you wait for the short sellers to start covering their positions. This often pushes the price higher and beyond any real valuation.

Short squeeze alert for September 14th: Two stocks that could see remarkable gains

Axcella Health (NASDAQ: AXLA ) stock is falling on Thursday following its announcement of a new Covid-19 treatment patent. However, it's not that this is bad news for the clinical-stage biotechnology company.

Why Is Axcella Health (AXLA) Stock Down 21% Today?

Axcella (AXLA) shares surge 299% after the company secures a methods-of-use patent for its lead candidate, AXA1125, which is currently under development to treat fatigue associated with Long Covid.

Axcella (AXLA) Up on Patent Grant for Long Covid Fatigue Drug

A little-known penny stock is among the market's top movers today. Axcella Health (NASDAQ: AXLA ) stock surged by as much as 280% on news that it has been granted an important new patent.

Why Is Axcella Health (AXLA) Stock Up 280% Today?

Axcella Health Inc (NASDAQ:AXLA) saw its stock rocket some 240% higher in Tuesday's early deals after the small-cap firm announced it had secured a patent for its treatment for ‘long' Covid fatigue. The company, in a statement, said its treatment candidate AXA1125, based on compositions of ‘endogenous metabolic modulators' (otherwise referred to as EMMs) had been granted a patent from the US Patent and Trademark Office.

Axcella Health stock rockets on long Covid patent win

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,737,999 with claims covering methods of use of Candidate AXA1125, for treating a subject having post-acute sequelae of COVID-19 (PASC), a/k/a Long CO.

Axcella Granted Patent for Long COVID Fatigue Treatment

Axcella Health (NASDAQ: AXLA ) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that would act as a catalyst for today's rally.

Why Is Axcella Health (AXLA) Stock Up 68% Today?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced financial results for the second quarter ended June 30, 2023 and provided a business update. “Patients are seeking relief from Long COVID fatigue. Axcella's proprietary composition of amino acids in AXA1125 in Long COVID fatigue i.

Axcella Reports Second Quarter Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarter ended March 31, 2023 and provided a business update. “Patients are seeking a Long COVID therapy, as we have seen represented at the recent BIO / Solve ME and FDA Patient Driven Drug Development Program forums.

Axcella Reports First Quarter Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced two oral presentations of results from the Phase 2a clinical trial of AXA1125 in the treatment of Long COVID Fatigue at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), as a hybrid event both online and in Cop

Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Axcella Health (NASDAQ: AXLA ) stock is on the rise Wednesday as investors react to an update from the FDA. That update has to do with the company's Long Covid  Fatigue treatment currently in development.

Why Is Axcella Health (AXLA) Stock Up 35% Today?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced its Investigational New Drug (IND) application to initiate a phase 2b/3 trial in the U.S. for AXA1125 in the treatment of Long COVID Fatigue has been cleared by the U.S. Food and Drug Administration (FDA).

Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that CEO Bill Hinshaw will present a company update at SVB Securities' 2023 Global Biopharma Conference, taking place virtually February 14-16, 2023.

Axcella Therapeutics to Participate in the SVB Securities' 2023 Global Biopharma Conference

BigBear.ai Holdings

Express

Fortuna Silver Mines

Jasper Therapeutics

LogicMark

OpGen

Penny stocks with news that has turned heads in the stock market this week. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 7 To Watch With Big News this Week

Penny stocks to watch after big news this week. The post 4 Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch With Big News This Week

Axcella Health (NASDAQ: AXLA ) stock is rocketing higher on Tuesday after revealing a regulatory path to registration for AXA1125. Investors will note that AXA1125 is the company's treatment for Long COVID Fatigue.

Why Is Axcella Health (AXLA) Stock Up 66% Today?

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, announced a regulatory path to registration of AXA1125 in the treatment of Long COVID Fatigue. The company reported that it had received regulatory guidance from The Medicines and Healthcare products Regulatory Agency (MHRA), the U.K.'s regulatory agency, supporting a single trial that could serve as the registration trial for patients with Long COVID fatigue, and aligning on key measurements, including primary endpoint and trial design. Axcella will be meeting with the MHRA in the near term to discuss the Innovative Licensing and Access Pathway (ILAP) application. The company further reported submission of an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for a Phase 2b/3 trial.

Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

Ambev

Camber Energy

Use these tools to find cheap penny stocks to buy The post How to Find Undervalued Penny Stocks: Quick Guide appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Find Undervalued Penny Stocks: Quick Guide

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Axcella Therapeutics (Nasdaq: AXLA), a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announces a repositioning of its strategy to focus on Long COVID and realize value from its platform and current programs. The company has initiated a process to explore a range of strategic alternatives to maximize shareholder value and is working with an investment bank to act as a strategic advisor for this process. As part of this repositioning, and to align with its current capital constraints, the company is announcing a series of organizational and program updates, including a reprioritization of its programs for Long COVID Fatigue and Nonalcoholic Steatohepatitis (NASH) and a restructuring of operations to support its streamlined set of priorities.

News for Axcella Health Inc Stock (AXLA)